Analyse critique de la littérature scientifique – Dr L. Greillier & Pr J. Mazières

  • 1er thème : Intercalated combination of chemotherapy and erlotinib for patients with Advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial

[pdf] article lecture critique 1[/pdf]

[pdf]jeudi lecture critique 1 _ L Greillier[/pdf]

 

  • 2nd thème : Next-Generation Sequencing Reveals High Concordance of Recurrent Somatic Alterations Between PrimaryTumor and Metastases From Patients With-Non-Small-Cell Lung Cancer

[pdf]article lecture critique 2 [/pdf]

[pdf]jeudi lecture critique 2 _ J Mazieres[/pdf]

Analyse critique de la littérature scientique : Pr Barlesi & Dr. Perol

  • 1er thème : Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

[pdf]F -Barlesi_Lux-Lung 1_ 2012[/pdf]

[pdf]LUX LUNG 1 _Miller Hirsch Cadranel.pdf

 

  • 2nd thème : Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

[pdf]M Pérol-Titan _GFPC 2012[/pdf]

[pdf]TITAN[/pdf]